Shanghai InnoStar Bio-tech Co

Shanghai InnoStar Bio-tech Co EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Shanghai InnoStar Bio-tech Co (688710.SS) as of Oct 19, 2026 is 266.83. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 29.50 — a change of 804.37% (higher).

EV/EBITDA

266.83

YoY

804.37%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Shanghai InnoStar Bio-tech Co is 2025 266.83 . EV/EBITDA (Enterprise Value to EBITDA) of Shanghai InnoStar Bio-tech Co was 2024 29.50 . It decreases by 804.37% higher compared to the previous year.

The Shanghai InnoStar Bio-tech Co EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2021
56.00 CNY
Jan 1, 2022
34.84 CNY
Jan 1, 2023
24.69 CNY
Jan 1, 2024
29.50 CNY
Jan 1, 2025
266.83 CNY
The Shanghai InnoStar Bio-tech Co EV/EBITDA history
YEAREV/EBITDAYoY
266.83+804.37%
29.50+19.51%
24.69-29.14%
34.84-37.79%
56.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai InnoStar Bio-tech Co Stock analysis

What does Shanghai InnoStar Bio-tech Co do? Shanghai InnoStar Bio-tech Co Ltd is a company based in Shanghai, China, operating within the Life Sciences Tools & Services sector of the Health Care industry. The company has 1,085 employees and completed its initial public offering (IPO) on September 3, 2024. It provides biopharmaceutical non-clinical research services, focusing on early drug development evaluation, non-clinical research, and clinical testing and translational research. The early drug development evaluation involves creating multiple early toxicity rapid prediction and screening models. Non-clinical research encompasses safety evaluation, pharmacokinetic research, and pharmacodynamic research. Clinical testing and translational research offers analytical methods and data support for clinical pharmacokinetics, efficacy, and safety studies related to innovative drug projects. The company's headquarters are located in Shanghai, and it maintains a website at www.innostar.cn. Its stock is listed under the ticker 688710.SS with ISIN CNE1000078J7. Shanghai InnoStar Bio-tech Co Ltd serves the biopharmaceutical sector by supporting the development and evaluation of new drugs through specialized research services. Shanghai InnoStar Bio-tech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai InnoStar Bio-tech Co stock

EV/EBITDA (Enterprise Value to EBITDA) of Shanghai InnoStar Bio-tech Co is 266.83 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Shanghai InnoStar Bio-tech Co changed from 29.50 to 266.83, representing a 804.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Shanghai InnoStar Bio-tech Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Shanghai InnoStar Bio-tech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Shanghai InnoStar Bio-tech Co

All Key Metrics — Shanghai InnoStar Bio-tech Co